Copyright
©The Author(s) 2023.
World J Clin Cases. Oct 26, 2023; 11(30): 7350-7362
Published online Oct 26, 2023. doi: 10.12998/wjcc.v11.i30.7350
Published online Oct 26, 2023. doi: 10.12998/wjcc.v11.i30.7350
Table 3 Efficacy of different comparisons of drugs for fusion rate by ORs and corresponding 95%CI
| Alendronate | 0.59 (0.15, 2.4) | 0.84 (0.11, 5.72) | 1.88 (0.64, 5.75) | 5.73 (0.48, 77.52) | 1 (0.17, 6.13) |
| 1.69 (0.42, 6.82) | Placebo | 1.42 (0.26, 7.05) | 3.17 (1.36, 7.77) | 9.66 (0.9, 121.89) | 1.69 (0.55, 5.37) |
| 1.19 (0.17, 8.76) | 0.7 (0.14, 3.89) | Risedronate | 2.24 (0.48, 12.08) | 6.85 (0.44, 123.81) | 1.2 (0.17, 9.35) |
| 0.53 (0.17, 1.57) | 0.32 (0.13, 0.74) | 0.45 (0.08, 2.1) | Teriparatide | 3.03 (0.33, 32.49) | 0.53 (0.13, 2.26) |
| 0.17 (0.01, 2.08) | 0.1 (0.01, 1.11) | 0.15 (0.01, 2.25) | 0.33 (0.03, 3.05) | Teriparatide + denosumab | 0.18 (0.01, 2.47) |
| 1 (0.16, 5.99) | 0.59 (0.19, 1.83) | 0.83 (0.11, 5.98) | 1.88 (0.44, 7.79) | 5.68 (0.4, 91.1) | Zoledronic acid |
- Citation: He XY, Chen HX, Zhao ZR. Efficacy and safety of different anti-osteoporotic drugs for the spinal fusion surgery: A network meta-analysis. World J Clin Cases 2023; 11(30): 7350-7362
- URL: https://www.wjgnet.com/2307-8960/full/v11/i30/7350.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i30.7350